FDA Approves Genentech’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
South San Francisco, CA — October 4, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: […]
SOUTH SAN FRANCISCO, Calif., July 18, 2018 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on […] A team of researchers affiliated with Novartis Institutes for Biomedical Research and Biometrics Matters Limited, has found via testing with […]inhibitors
Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
Testing suggests TORC1 inhibitors can boost immune system in the elderly